AbbVie (ABBV) Competitors

Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Do analysts rate AMGN or ABBV?

Amgen presently has a consensus target price of $307.82, suggesting a potential upside of 4.48%. AbbVie has a consensus target price of $211.29, suggesting a potential upside of 11.64%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.35
AbbVie	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.81

Is AMGN or ABBV a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.5%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 279.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the media prefer AMGN or ABBV?

In the previous week, AbbVie had 36 more articles in the media than Amgen. MarketBeat recorded 96 mentions for AbbVie and 60 mentions for Amgen. Amgen's average media sentiment score of 1.43 beat AbbVie's score of 0.72 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	49 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	61 Very Positive mention(s)	10 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in AMGN or ABBV?

76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.8% of Amgen shares are held by insiders. Comparatively, 0.3% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has higher valuation and earnings, AMGN or ABBV?

AbbVie has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.74	$4.09B	$10.96	26.88
AbbVie	$57.37B	5.83	$4.28B	$2.35	80.54

Is AMGN or ABBV more profitable?

Amgen has a net margin of 17.39% compared to AbbVie's net margin of 7.31%. AbbVie's return on equity of 412.03% beat Amgen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	17.39%	176.11%	12.39%
AbbVie	7.31%	412.03%	13.11%

Which has more risk & volatility, AMGN or ABBV?

Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Summary

AbbVie beats Amgen on 13 of the 20 factors compared between the two stocks.